1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Beijing Aosaikang Pharmaceutical Co., Ltd.

Beijing Aosaikang Pharmaceutical Co., Ltd.

002755.SZ
Beijing Aosaikang Pharmaceutical Co., Ltd.CN flagShenzhen Stock Exchange
14.63
CNY
-0.55
- -
13.58BMarket Cap
Beijing Aosaikang Pharmaceutical Co., Ltd.
002755.SZ
(Shenzhen Stock Exchange)

Recent

price

14.63

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
4.12
3.83
3.87
3.62
1.82
1.14
4.48
5.22
4.86
4.09
3.35
1.99
1.55
1.89
1.88
2.04
Revenue per Share
0.38
0.46
0.43
0.29
0.12
0.03
0.8
0.89
0.84
0.78
0.41
-0.24
-0.16
0.17
0.25
0.27
Basic EPS, GAAP
-0.05
0.79
-0.12
-0.29
-0.02
0.08
0.78
0.53
0.39
0.41
0.47
-0.22
-0.17
0.19
0.54
-0.23
Free Cash Flow per Basic Share
0.06
0.09
0.09
0.09
0.05
0.02
1.39
- -
0.13
0.22
0.2
0.1
- -
- -
0.12
0.09
Dividend per Share
1.54
1.87
2.17
2.33
2.21
2.16
1.12
2.17
2.43
3.01
3.21
2.82
2.7
2.83
2.95
2.98
Book Value per Share
1.66
2.03
2.37
2.56
3.31
3.22
1.52
2.34
2.52
2.93
3.04
2.66
2.57
2.49
2.45
2.55
Tangible Book Value per Share
129
129
129
130
153
157
759
753
930
925
927
941
928
943
946
912
Basic Weighted Avg Shares
529
494
500
471
278
178
3,405
3,932
4,519
3,783
3,107
1,873
1,443
1,778
1,779
1,862
Sales/Revenue/Turnover
12.21
15.83
14.27
14.25
12.21
-3.29
19.62
18.44
19.04
19.83
11.45
-15.08
-17.89
6.64
13.31
10.99
Operating Margin (%)
- -
4
4
4
4
4
72
83
88
93
95
92
85
88
129
- -
Depreciation Expense
49
60
56
38
19
5
608
670
781
722
380
-226
-149
160
237
245
Net Income, GAAP
14.99
15.88
15.43
16.58
18.04
0.87
13.16
11.4
12.17
11.67
6.28
- -
- -
15.18
15.56
8.28
Effective Tax Rate (%)
9.29
12.13
11.09
7.96
6.78
2.58
17.84
17.04
17.28
19.08
12.23
-12.06
-10.29
9.02
13.3
13.14
Profit Margin (%)
169
252
261
286
458
457
424
1,040
1,556
1,954
2,085
1,814
1,755
1,747
1,824
1,749
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
14
12
9
7
7
4
5
LT Debt
215
263
308
334
508
509
1,242
1,848
2,517
3,033
3,228
3,013
3,011
3,142
3,274
3,208
Total Equity
- -
25.9
20.93
18.6
7.2
-1.25
68.77
41.7
34.41
23.42
10.42
- -
- -
3.15
6.09
5.81
Return on Invested Capital (%)
- -
27.32
21.31
12.73
5.59
0.38
100.25
53.31
39.99
28.31
13.16
- -
- -
6.99
9.12
9.9
Return on Capital (%)
- -
27.32
21.31
12.86
5.89
1.36
101.89
53.79
40.04
28.61
13.2
-8.02
-5.75
6.19
8.66
9.23
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
66
51
50
LT Borrowings
- -
- -
- -
LT Finance Leases
7
4
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
928
928
928
Market Capitalization
13,364
16,492
14,577

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
2,568
2,776
2,863
Cash, Cash Equivalents & STI
2,095
2,282
2,372
Accounts Receivable, Net
175
196
242
Inventories
197
188
151
Total Current Liabilities
821
940
1,114
Payables & Accruals
- -
- -
- -
ST Debt
66
51
50
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
25.78%
1.65%
4.2%
Free Cash Flow
385.98%
-38.29%
180.79%
Net Income, GAAP
1,263.63%
-80.27%
47.6%
Sales/Revenue/Turnover
173%
-11.46%
0.08%
Total Cash Common Dividend
6,270.25%
1,874.27%
9,526.49%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
448
474
462
393
1,778
2025
509
499
345
- -
1,779
2026
482
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
- -
- -
- -
0.17
2025
0.06
- -
- -
- -
0.25
2026
0.09
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
0.12
2026
- -
- -
- -
- -
- -
Similar Companies
Evotec SE (0IRF.IL)
Beijing SL Pharmaceutical Co., Ltd. (002038.SZ)
SLANG Worldwide Inc. (SLNG.CN)
Medico Remedies Limited (MEDICO.BO)
Emergent Health Corp (EMGE)
Lansen Pharmaceutical Holdings Limited (0503.HK)
Business
Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ) researches, develops, manufactures, markets and sells pharmaceuticals, fine chemicals and health-care products primarily in oncology, gastroenterology, antibiotic and anti-infective therapeutic areas in China. The company offers proton pump inhibitor injections including omeprazole sodium for injection, dexlansoprazole for injection, esomeprazole sodium for injection, lansoprazole for injection and rabeprazole sodium for injection; oncology medicines such as liotinib tablets, trifluoruridine tipipyrimidine tablets, neratinib maleate tablets, temozolomide capsules, lenvatinib mesylate capsules, decitabine for injection and dexrazoxane for injection; anti-infectives including polymyxin E sodium mesylate for injection, voriconazole for injection and daptomycin for injection; and other products like saxagliptin tablets and parecoxib sodium for injection. Through its subsidiary Jiangsu Aosaikang Pharmaceutical Co., Ltd., it produces proton pump inhibitors and operates from headquarters in Nanjing, China, where the company was founded in 2003. Recent developments include an exclusive license agreement with Shield Therapeutics for the development and commercialization of ACCRUFeR/Feraccru in China, Hong Kong, Macau and Taiwan; participation in innovation-driven M&A and licensing partnerships as part of Chinese pharma's embrace of European technologies; clinical trial approvals for ASKC202 and ASK120067 tablets combination for non-small cell lung cancer; and revenue growth in anti-infectives and chronic disease products exceeding 50% year-on-year in 2024.